Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)

1. Pérez-Martínez, L.
2. Pérez-Matute, P.
3. Aguilera-Lizarraga, J.
4. Rubio-Mediavilla, S.
5. Narro, J.
6. Recio, E.
7. Ochoa-Callejero, L.
8. Oteo, J.-A.
9. Blanco, J.-R.